...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Endocrine Disorders >Glucose control in intensive care: usability, efficacy and safety of Space GlucoseControl in two medical European intensive care units
【24h】

Glucose control in intensive care: usability, efficacy and safety of Space GlucoseControl in two medical European intensive care units

机译：重症监护中的血糖控制：欧洲两个医疗重症监护室中Space GlucoseControl的可用性，功效和安全性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background The Space GlucoseControl system (SGC) is a nurse-driven, computer-assisted device for glycemic control combining infusion pumps with the enhanced Model Predictive Control algorithm (B. Braun, Melsungen, Germany). We aimed to investigate the performance of the SGC in medical critically ill patients. Methods Two open clinical investigations in tertiary centers in Graz, Austria and Zurich, Switzerland were performed. Efficacy was assessed by percentage of time within the target range (4.4-8.3?mmol/L; primary end point), mean blood glucose, and sampling interval. Safety was assessed by the number of hypoglycemic episodes (≤2.2?mmol/L) and the percentage of time spent below this cutoff level. Usability was analyzed with a standardized questionnaire given to involved nursing staff after the trial. Results Forty medical critically ill patients (age, 62?±?15?years; body mass index, 30.0?±?8.9?kg/m2; APACHE II score, 24.8?±?5.4; 27 males; 8 with diabetes) were included for a period of 6.5?±?3.7?days (n?=?20 in each center). The primary endpoint (time in target range 4.4 to 8.3?mmol/l) was reached in 88.3%?±?9.3 of the time and mean arterial blood glucose was 6.7?±?0.4?mmol/l. The sampling interval was 2.2?±?0.4?hours. The mean daily insulin dose was 87.2?±?64.6?IU. The adherence to the given insulin dose advice was high (98.2%). While the percentage of time spent in a moderately hypoglycemic range (2.2 to 3.3?mmol/L) was low (0.07?±?0.26% of the time), one severe hypoglycemic episode ( Conclusions SGC is a safe and efficient method to control blood glucose in critically ill patients as assessed in two European medical intensive care units.
机译：背景技术太空葡萄糖控制系统（SGC）是由护士驱动的计算机辅助设备，用于将输液泵与增强的模型预测控制算法（B. Braun，Melsungen，德国）结合起来进行血糖控制。我们旨在研究SGC在危重病患者中的表现。方法在奥地利格拉茨和瑞士苏黎世的三级中心进行了两次公开临床研究。通过在目标范围内的时间百分比（4.4-8.3？mmol / L;主要终点），平均血糖和采样间隔来评估疗效。通过降血糖发作的次数（≤2.2？mmol / L）和在此临界值以下花费的时间百分比来评估安全性。在试验后，通过向参与的护理人员提供的标准化问卷对可用性进行了分析。结果40名危重病患者（年龄62？±？15？岁;体重指数：30.0？±？8.9？kg / m 2 ; APACHE II评分：24.8？±？5.4; 27男性; 8名糖尿病患者）的住院时间为6.5？±？3.7？天（每个中心的n？=？20）。主要终点（时间在目标范围4.4至8.3？mmol / l）达到了88.3％？±？9.3，平均动脉血糖为6.7？±？0.4？mmol / l。取样间隔为2.2±±0.4小时。每日平均胰岛素剂量为87.2±64.6IU。对给定的胰岛素剂量建议的依从性很高（98.2％）。虽然在中等降血糖范围（2.2至3.3？mmol / L）中花费的时间百分比很低（占时间的0.07？±？0.26％），但发生了一次严重的降血糖事件（结论SGC是一种安全有效的控制血液的方法在两个欧洲医疗重症监护病房中评估的危重患者血糖水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号